ReviewWorld journal of gastroenterology2009
Adenosine: an immune modulator of inflammatory bowel diseases.
Review in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- Dynamic Cultivation ofFoods (Basel, Switzerland) · 2026Article
- Evaluating fecal inflammation biomarkers for non-invasive detection of weaning-related intestinal inflammation in piglets.Journal of animal science · 2026Article
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Intestinal Clock Promotes Cognitive Memory Through Adenosine Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Untargeted Analysis of Serum Metabolomes in Dogs with Exocrine Pancreatic Insufficiency.Animals : an open access journal from MDPI · 2023Article
- GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease.Bioactive materials · 2023Article
- A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases.Life (Basel, Switzerland) · 2021Article
- Microbiota and Drug Response in Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2021Review
- Intestinal Regulatory T Cells.Advances in experimental medicine and biology · 2021Article
- Decreased Frequency of Intestinal CD39Frontiers in immunology · 2020Article
- Preventive effects of guanosine on intestinal inflammation in 2, 4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rats.Inflammopharmacology · 2019Article
- Comparative Computational and Experimental Detection of Adenosine Using Ultrasensitive Surface-Enhanced Raman Spectroscopy.Sensors (Basel, Switzerland) · 2018Article
- Dynamics of metatranscription in the inflammatory bowel disease gut microbiome.Nature microbiology · 2018Article
- MicroRNA in gastrointestinal cell signalling.Inflammopharmacology · 2018Review
- Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases.Frontiers in pharmacology · 2018Review
- Adenosine: Direct and Indirect Actions on Gastric Acid Secretion.Frontiers in physiology · 2017Review
- Nopal feeding reduces adiposity, intestinal inflammation and shifts the cecal microbiota and metabolism in high-fat fed rats.PloS one · 2017Article
- Article
- Blunted dynamics of adenosine A2A receptors is associated with increased susceptibility to Candida albicans infection in the elderly.Oncotarget · 2016Article
- MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inflammatory bowel disease (IBD) is a common and lifelong disabling gastrointestinal disease. Emerging treatments are being developed to target inflammatory cytokines which initiate and perpetuate the immune response. Adenosine is an important modulator of inflammation and its anti-inflammatory effects have been well established in humans as well as in animal models. High extracellular adenosine suppresses and resolves chronic inflammation in IBD models. High extracellular adenosine levels could be achieved by enhanced adenosine absorption and increased de novo synthesis. Increased adenosine concentration leads to activation of the A2a receptor on the cell surface of immune and epithelial cells that would be a potential therapeutic target for chronic intestinal inflammation. Adenosine is transported via concentrative nucleoside transporter and equilibrative nucleoside transporter transporters that are localized in apical and basolateral membranes of intestinal epithelial cells, respectively. Increased extracellular adenosine levels activate the A2a receptor, which would reduce cytokines responsible for chronic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.